Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (42522)	5/5/2010 8:07:14 PM
From: Rangle	Read Replies (1) \| Respond to of 48463

Nice trade pn the spoos I didn't take it I banked a nice ES trade Mon not taking any ONT 's right now .

To: Bucky Katt who wrote (42522)	1/19/2011 7:10:25 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48463

ARIA into $7 & new high, smoking... ARIAD Pharmaceuticals, Inc. (ARIA, Trade ), today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. Merck is currently developing ridaforolimus in multiple cancer indications under an exclusive license and collaboration agreement with ARIAD. Complete findings from the SUCCEED trial will be submitted for presentation at an upcoming medical meeting this year.